Triumvira Expands Management Team with Chief Medical Officer and VP of Finance

Innovative immuno-therapy company welcomes proven leaders in pharma
and therapeutics

, a privately held biopharmaceutical company developing
a novel platform for engineering T cells to attack cancers, today
announced the formal appointments of Sabine Chlosta, MD, PhD, as Chief
Medical Officer, and Jon Irvin as Vice President of Finance.

“We are delighted to expand our executive management team with Dr.
Chlosta and Mr. Irvin,” said Paul Lammers, MD, MSc., President and CEO
of Triumvira Immunologics. “We look forward to leveraging Sabine’s
extensive experience in immuno-oncology and clinical trial oversight as
we work to develop and commercialize innovative therapies that will
empower a patient’s own immune system to tackle serious and
life-threatening diseases.”

“In addition, Jon’s finance expertise in the pharmaceutical and
technology industries will be a strong asset to Triumvira as we build
our company to bring new treatments to patients in need,” Lammers added.

Prior to Triumvira, Sabine Chlosta consulted for Aurora BioPharma, a
start-up company developing CAR-T cells in solid tumors and was
previously a Senior Medical Director at Merck & Co. where she played a
key role in the development of its PD-1 inhibitor Keytruda®
in Non-Hodgkin’s lymphoma and oversaw trials in other indications, as
well. Earlier in her career, Dr. Chlosta was a medical director at
Glycomimetics where she helped launch the company’s first trial in
cancer. She began her industry career as a Fellow in Oncology Drug
Development at Novartis overseeing clinical pharmacology trials with a
small molecule and helped launch their CAR-T lymphoma program with
Kymriah®. Dr. Chlosta is a board-certified pediatric
hematologist oncologist out of Memorial Sloan-Kettering Cancer Center
and Weill Cornell Medical College.

“Triumvira is poised for growth and success in T cell therapy, and I am
thrilled to be part of the team to take our innovative TAC technology
into the clinic,” said Dr. Chlosta.

Jon Irvin was the Chief Financial Officer and Vice President of Finance
at Mirna Therapeutics, a publicly traded biotechnology company, before
joining Triumvira. He also served in executive financial positions for
Voxpath Networks, Inc., a telecommunications and intellectual property
company, Reddwerks Corporation, a software company, Esoterix, Inc., a
medical laboratory company, Topaz Technologies, a pharmaceutical
software company, and BioNumerik Pharmaceuticals, Inc., a pharmaceutical
company. Mr. Irvin previously worked with Ernst & Young’s life science
practice in Palo Alto, California.

Irvin commented, “It’s exciting to be a part of this growing team as we
develop our novel platform to treat patients’ unmet medical needs.”

About Triumvira Immunologics

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company
co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and
Bloom Burton & Co., with the vision of developing novel T cell therapies
that are safer and more efficacious than current gene therapy cancer
treatments, including chimeric antigen receptor (CAR) and engineered T
cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler
(TAC) technology recruits the entire natural T cell receptor and is
independent of the Major Histocompatibility Complex (MHC), allowing for
the development of better therapies for a broader range of patients with
solid or liquid malignancies and with diseases other than cancer. With
operations spanning North America, our corporate offices are located in
Austin, Texas, with our research facilities in Hamilton, Ontario. For
more information, visit
or send email inquiries to


Beth Kurth, +1 617-374-8800, Ext. 106
President, Investor Relations & Corporate Communications